A rapid at-home test for SARS-CoV-2

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:1 publications

Grant number: 172718

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2020
  • Known Financial Commitments (USD)

    $985,562.25
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principle Investigator

    Pending
  • Research Location

    Canada, Americas
  • Lead Research Institution

    McMaster University Biochemistry and Biomedical Sciences
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

As governments move toward re-opening Canada, it is critical that we have in place fast and simple tests for COVID-19. Canada needs cost-effective diagnostic technologies that allow for accurate and real-time mass testing in a variety of places, such as homes, airports, doctors' offices, borders, long-term care facilities and remote locations without access to centralized testing facilities. The goal of this proposal is to adapt and optimize existing technologies, originally developed by a team of researchers at McMaster University for bacterial detection, into a rapid point-of-need test for COVID-19. The test targets two classes of unique biomarkers - RNA and proteins - from COVID-19 to increase the test accuracy. It targets the RNA using molecular scissors made of DNA (called DNAzymes) and the proteins using molecular hands made of DNA (called DNA aptamers). These molecular scissors and hands will convert the presence of viral RNA and proteins to a DNA output, which is then massively amplified via an equipment-free room-temperature amplification method, known as "rolling circular amplification" (RCA), making the test highly sensitive. The device for the test is very simple and cheap, resembling a home pregnancy test. The test uses saliva as the sample source and fast chemical and biochemical reactions so that the test can be performed easily within 30 minutes by untrained users at home or any other points of need. Test reagents are contained in tablets for user convenience and high stability. Our team has already obtained proof-of-concept for most of the components of the test and will aim to optimize and integrate these components into a test kit, and validate the test by working with clinicians at the frontline of COVID-19 diagnostics and treatment. We are also working with Canadian industrial partners who can help with manufacturing and distribution of tests and recording of test results.

Publicationslinked via Europe PMC

Last Updated:39 minutes ago

View all publications at Europe PMC

Investigation of discordant SARS-CoV-2 RT-PCR results using minimally processed saliva.